Literature DB >> 10648491

Induction of atrial fibrillation with rapid high voltage ventricular pacing for ventricular fibrillation conversion testing. The Ventak AV II DR Study.

A Schuchert1, M Kühl, R Rüppel, T Meinertz.   

Abstract

OBJECTIVE: To assess whether rapid high voltage ventricular pacing can also induce atrial fibrillation, and whether the induction of atrial fibrillation during ventricular fibrillation conversion testing is related to the patient's heart disease.
DESIGN: Prospective study of 50 patients who received the dual chamber implantable cardioverter-defibrillator (ICD) Ventak AV II DR (Guidant) as a first implant. This device can record atrial activity even during a ventricular fibrillation episode and can induce atrial fibrillation by rapid atrial bursts. MAIN OUTCOME MEASURES: Frequency of atrial fibrillation after induction of ventricular fibrillation; clinical characteristics of patients with and without induced atrial fibrillation; frequency of atrial fibrillation induced by rapid atrial bursts during predischarge testing.
RESULTS: Atrial fibrillation was observed in 40 of the 217 ventricular fibrillation episodes (18%) that could be detected immediately after delivery of high voltage pacing. The biphasic ICD shock for termination of ventricular fibrillation also terminated the atrial fibrillation in all cases. The 40 episodes of simultaneous atrial and ventricular fibrillation occurred in 18 patients (36%). The distribution of the clinical characteristics of the patients and the inducibility of atrial fibrillation during predischarge testing were similar in those with and without induced atrial fibrillation.
CONCLUSIONS: Rapid high voltage ventricular pacing frequently induces atrial fibrillation, which was terminated by the subsequent biphasic ICD shock. The induction of atrial fibrillation seems to be a non-specific phenomenon, unrelated to the clinical status of the patient.

Entities:  

Mesh:

Year:  2000        PMID: 10648491      PMCID: PMC1729296          DOI: 10.1136/heart.83.2.178

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  Coronary sinus pacing prevents induction of atrial fibrillation.

Authors:  P Papageorgiou; F Anselme; C J Kirchhof; K Monahan; C A Rasmussen; L M Epstein; M E Josephson
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

Review 2.  Atrial vulnerability.

Authors:  F G Cosio
Journal:  Clin Cardiol       Date:  1992-03       Impact factor: 2.882

3.  Transvenous single lead atrial defibrillation: efficacy and risk of ventricular fibrillation in an ischemic canine model.

Authors:  S Osswald; T G Trouton; M Roelke; S S O'Nunain; J T Fallon; H B Holden; J N Ruskin; H Garan
Journal:  Pacing Clin Electrophysiol       Date:  1998-03       Impact factor: 1.976

4.  Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators.

Authors:  T J Florin; D N Weiss; R W Peters; S R Shorofsky; M R Gold
Journal:  Am J Cardiol       Date:  1997-10-01       Impact factor: 2.778

5.  Atrial fibrillation/flutter induced by implantable ventricular defibrillator shocks: difference between epicardial and endocardial energy delivery.

Authors:  A Katz; J J Evans; R I Fogel; J J Schier; R G Matheny; G M Baranowski; E N Prystowsky
Journal:  J Cardiovasc Electrophysiol       Date:  1997-01

6.  Sensitivity and specificity of programmed atrial stimulation for induction of supraventricular tachycardias.

Authors:  A S Manolis; J Cameron; T Deering; E H Han; N A Estes
Journal:  Clin Cardiol       Date:  1988-05       Impact factor: 2.882

7.  Electrophysiologic effects and efficacy of cibenzoline on stimulation-induced atrial fibrillation and flutter and implications for treatment of paroxysmal atrial fibrillation.

Authors:  V Kühlkamp; J Meerhof; F Schmidt; F Mayer; O Ickrath; R Haasis; L Seipel
Journal:  Am J Cardiol       Date:  1990-03-01       Impact factor: 2.778

8.  Comparison of the defibrillation threshold and the upper limit of ventricular vulnerability.

Authors:  P S Chen; N Shibata; E G Dixon; R O Martin; R E Ideker
Journal:  Circulation       Date:  1986-05       Impact factor: 29.690

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.